Key result
Current abacavir use linked to ~87% greater CAD risk in people living with HIV.
Why the study?
People living with HIV are at increased risk for coronary artery disease, prompting this study to describe the features associated with coronary artery disease in this population.
What factors are associated with the development of coronary artery disease in people living with HIV?
Case-Control (n=477)
No
What factors are associated with the development of coronary artery disease in people living with HIV?
Odds Ratio: 1.87 (95% CI 1.14–3.07)
Absolute Event Rate: 34.4% vs 24.9%
p-value: p=0.023
Traditional cardiovascular risk factors and exposure to abacavir are significantly associated with the development of coronary artery disease in people living with HIV.
Supports CAD vigilance with abacavir in HIV; hypothesis-generating and should not yet change practice.
BACKGROUND: People living with HIV (PLHIV) are at increased risk for coronary artery disease (CAD). This study aimed to describe the features associated with CAD in PLHIV. METHODS: A case ([n =160] PLHIV with CAD) control ([n =317] PLHIV matched by age and sex without CAD) study was performed at the Alfred Hospital, Melbourne, Australia (January 1996 and December 2018). Data collected included CAD risk factors, duration of HIV infection, nadir and at-event CD4+ T-cell counts, CD4:CD8 ratio, HIV viral load, and antiretroviral therapy exposure. RESULTS: Participants were predominantly male (n =465 [97.4%]), with a mean age of 53years. Traditional risk factors associated with CAD in univariate analysis included hypertension (OR 11.4 [95%CI 5.01, 26.33], P <0.001), current cigarette smoking (OR 2.5 [95% CI 1.22, 5.09], P =0.012), and lower high-density lipoprotein cholesterol (OR 0.14 [95%CI 0.05, 0.37], P <0.001). There was no association between duration of HIV infection, nadir or current CD4 cell count. However, current and ever exposure to abacavir (cases: 55 [34.4%]; controls: 79 [24.9%], P =0.023 and cases: 92 [57.5%]; controls: 154 [48.6%], P =0.048, respectively) was associated with CAD. In conditional logistic regression analysis, current abacavir use, current smoking, and hypertension remained significantly associated (aOR=1.87 [CI=1.14, 3.07], aOR=2.31 [1.32, 4.04], and aOR=10.30 [5.25, 20.20] respectively). CONCLUSION: Traditional cardiovascular risk factors and exposure to abacavir were associated with CAD in PLHIV. This study highlights that aggressive management of cardiovascular risk factors remains critical for reducing risk in PLHIV.
No takes yet. Share an insight, caveat, or question.
Mushin et al. (2023) conducted a case-control in Coronary artery disease in people with HIV (n=477). Current abacavir use vs. No current abacavir use was evaluated on Coronary artery disease (aOR 1.87, 95% CI 1.14, 3.07, p=0.023). Current abacavir use was significantly associated with the development of coronary artery disease in people living with HIV (aOR 1.87; 95% CI 1.14-3.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: